Roche Holding AG Genussscheine (ROGP) Stock Price & News

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in the Forbes Global 2000 was 76. The company owns the American biotechnology company Genentech, which is a wholly owned independent subsidiary, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States–based companies Ventana and Foundation Medicine. Roche's revenues during fiscal year 2020, were 58.32 billion Swiss francs. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights, with Swiss pharma firm Novartis owning a further third of its shares until 2021. F. Hoffmann-La Roche is a full member of the European Federation of Pharmaceutical Industries and Associations. Wikipedia

About Roche Holding AG Genussscheine

CEOThomas Schinecker

Employees113K

FoundedOct 1, 1896

HeadquartersBasel, Basel City, Switzerland

SectorPharmaceutical industry

Websiteroche.com

All values in CHF	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	15.75B	15.75B	15.73B	15.73B
Cost of goods sold	4.21B	4.21B	3.93B	3.93B
Cost of revenue	4.21B	4.21B	3.93B	3.93B
Research and development expenses	3.15B	3.15B	2.99B	2.99B
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	3.59B	3.59B	3.22B	3.22B
Operating expense	6.82B	6.82B	6.11B	6.11B
Total operating expenses	11.03B	11.03B	10.03B	10.03B
Operating income	4.72B	4.72B	5.69B	5.69B
Other non operating income	-10.00M	-10.00M	-15.00M	-15.00M
EBT including unusual items	3.69B	3.69B	4.49B	4.49B
EBT excluding unusual items	4.37B	4.37B	5.38B	5.38B
Income tax expense	709.00M	709.00M	824.00M	824.00M
Effective tax rate	19.20%	19.20%	18.37%	18.37%
Other operating expenses	77.50M	77.50M	-99.00M	-99.00M
Net income	2.74B	2.74B	3.44B	3.44B
Net profit margin	17.36%	17.36%	21.85%	21.85%
Earnings per share	-	-	-	-
Interest and investment income	45.00M	45.00M	43.50M	43.50M
Interest expense	-289.50M	-289.50M	-282.00M	-282.00M
Net interest expenses	-244.50M	-244.50M	-238.50M	-238.50M
Depreciation and amortization charges	-	-	-	-
EBITDA	5.50B	5.50B	6.48B	6.48B
Gain or loss from assets sale	-21.50M	-21.50M	-2.50M	-2.50M

Ask anything